Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia

Kasturi, Sanjay; Russell, Shane T.; McVary, Kevin T.

doi:10.1007/s11934-996-0008-y

Cited by 89 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IGF-1 is a strong mitogen; it increases cell proliferation and induces apoptosis in many tissues, including prostatic stroma and epithelium [21]. Similarly, increased glucose levels are likely to be accompanied by hyperinsulinemia, which results in an increase in IGF and induces a reduction in proapoptotic cascades within the prostate [22]. These changes should culminate in increased prostate growth.…”

Section: Discussionmentioning

confidence: 99%

Association of Metabolic Syndrome and Benign Prostatic Hyperplasia in Chinese Patients of Different Age Decades

Pan¹,

Jiang²,

Luo³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Objectives: To evaluate the relationship between metabolic syndrome (MetS) and annual prostate growth rates in Chinese patients of different age decades with benign prostatic hyperplasia (BPH). Methods: We retrospectively analyzed the clinical data obtained from 1,052 Chinese men with BPH. Overnight fasting venous blood specimens were collected and serum levels of prostate-specific antigen, fasting blood glucose, high-density lipoprotein cholesterol, total cholesterol and triglyceride were recorded. We divided age into four groups: 50 ≤ age ≤ 60, 60 < age ≤ 70, 70 < age ≤ 80 and 80 < age ≤ 90. Pearson's correlation coefficient was used to test the linearity of the relationships between each of the MetS components and prostate volume and annual prostate growth rates generally and in different age decades. Results: The median total prostate volume (69.01 ml) and median annual prostate growth rate (1.92 ml/year) were significantly higher in the MetS group compared with the non-MetS group (57.26 ml and 1.23 ml/year). Significant positive correlations were also found in total prostate volume and different age decades, while negative correlations were seen in annual prostate growth rate and different age decades. Conclusions: MetS is associated with an increased risk of total volume and annual prostate growth rate in BPH patients of different age decades.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Metabolic Syndrome and Benign Prostatic Hyperplasia in Chinese Patients of Different Age Decades

Pan¹,

Jiang²,

Luo³

et al. 2013

Urol Int

View full text Add to dashboard Cite

show abstract

“…However, central obesity may adversely impact LUTS independent of the prostate growth, as demonstrated by changes in severity of LUTS in men after prostatectomy [31323334]. An emerging body of evidence suggests that a relationship exists between LUTS severity and Met S [3233353637]. As reported by Kupelian et al [38], Met S was significantly associated with an elevated American Urological Association-symptom index score (multivariate odds ratio [OR]=1.68).…”

Section: Introductionmentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

Lower urinary tract function is modulated by neural, vascular and urethral and bladder structural elements. The pathophysiological mechanisms of lower urinary tract symptoms (LUTS) encompass prostate enlargement, alterations in urethra histological structure bladder fibrosis and alterations in pelvic neuronal and vascular networks, The complex pathophysiological relationship between testosterone (T) deficiency (TD) and the constellations LUTS, and metabolic dysfunction manifested in the metabolic syndrome (Met S) remains poorly understood. TD has emerged as one the potential targets by which Met S may contribute to the onset and development as well as worsening of LUTS. Because it has been recognized that treatment of men with Met S with T therapy ameliorates Met S components, it is postulated that T therapy may represent a therapeutic target in improving LUTS. Furthermore, the effect of TD on the prostate remains unclear, and often debatable. It is believed that T exclusively promotes prostate growth, however recent evidence has strongly contradicted this belief. The true relationship between benign prostatic hyperplasia, TD, and LUTS remains elusive and further research will be required to clarify the role of T in both benign prostatic hypertrophy (BPH) and LUTS as a whole. Although there is conflicting evidence about the benefits of T therapy in men with BPH and LUTS, the current body of literature supports the safety of using this therapy in men with enlarged prostate. As the population afflicted with obesity epidemic continues to age, the number of men suffering from Met S and LUTS together is expected to increase.

show abstract

“…The components of this syndrome are type II diabetes mellitus, hypertension, obesity, and dyslipidemia. These components are proposed as risk factors for the development of prostatic hyperplasia [4,5]. …”

Section: Introductionmentioning

confidence: 99%

Association of Metabolic Syndrome and Benign Prostate Enlargement in Young Korean Males

Jeong

Kim

2011

Korean J Urol

View full text Add to dashboard Cite

PurposeThis study was designed to evaluate the association of metabolic syndrome and benign prostate enlargement in young Korean males. We analyzed the clinical data associated with metabolic syndrome and prostate volume in the study population.Materials and MethodsWe retrospectively analyzed the clinical data obtained from 1,506 young men under the age of 60 who visited the health promotion center in our institution for routine checkups. The patients were interviewed with a questionnaire including the International Prostate Symptom Score (IPSS) and were evaluated by medical history, blood chemistry, digital rectal examination, and prostate volume via transrectal ultrasonography. The presence of metabolic syndrome was determined according to the modified National Cholesterol Education Program Expert Panel on Detection, Evalution, And Treatment of High Blood Cholesterol in Adults criteria. We divided the subjects into two groups: those with metabolic syndrome and those without. Logistic regression analysis was carried out to determine which metabolic components were associated with an increased risk of benign prostate enlargement.ResultsSignificant differences in prostate volume were noted between the groups. The prostate volumes were significantly larger in the metabolic syndrome group than in the non-metabolic syndrome group in all subgroups divided by age (in decades). However, no significant differences in IPSS or voiding or storage subscore were noted. In the multivariate regression analysis, only diabetes and obesity were identified as risk factors for benign prostate enlargement among the metabolic components.ConclusionsMetabolic syndrome and prostate volume were significantly related, even in young males. Diabetes and obesity were identified as significant risk factors for benign prostate enlargement in young males under the age of 60.

show abstract

Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia

Cited by 89 publications

References 24 publications

Association of Metabolic Syndrome and Benign Prostatic Hyperplasia in Chinese Patients of Different Age Decades

Association of Metabolic Syndrome and Benign Prostatic Hyperplasia in Chinese Patients of Different Age Decades

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Association of Metabolic Syndrome and Benign Prostate Enlargement in Young Korean Males

Contact Info

Product

Resources

About